Neogenomics Intrinsic Stock Value – Needham: Limited Impact of NeoGenomics Ruling on Estimates
December 30, 2023
🌧️Trending News
NEOGENOMICS ($NASDAQ:NEO): Needham recently released a statement noting that they believe the recent ruling on NeoGenomics will have a limited impact on their estimates. NeoGenomics is a leading provider of cancer-focused genetic testing services. The company offers a comprehensive range of genetic testing services across the United States and Europe, providing actionable insights to the healthcare sector for diagnosis, treatment selection, and monitoring of cancer patients.
Needham believes that the ruling will have a limited effect on their estimates as it does not impact the core fundamentals of NeoGenomics’ business. They remain optimistic about the company’s continued growth prospects and expect its share price to continue to appreciate in the near future.
Share Price
On Thursday, NeoGenomics stock opened at $18.0 and closed at $16.8, plummeting by 18.1% from its prior closing price of 20.5. This significant drop was due to a ruling concerning NeoGenomics’ patent infringement case against PathGroup, which held that PathGroup did not infringe on the NeoGenomics patents. This ruling does not have much impact on the estimates of NeoGenomics as the company is expected to remain profitable and continue to perform well in the future. Furthermore, the ruling does not have any effect on NeoGenomics’ competitive position in the industry, as it is still one of the leading companies in the field. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Neogenomics. More…
| Total Revenues | Net Income | Net Margin |
| 574.8 | -96.33 | -14.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Neogenomics. More…
| Operations | Investing | Financing |
| -23.42 | 58.45 | 5.09 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Neogenomics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.68k | 730.81 | 7.44 |
Key Ratios Snapshot
Some of the financial key ratios for Neogenomics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.6% | 29.1% | -18.4% |
| FCF Margin | ROE | ROA |
| -8.6% | -6.9% | -3.9% |
Analysis – Neogenomics Intrinsic Stock Value
We at GoodWhale have taken a deep dive into NEOGENOMICS’ fundamentals in order to provide our users with a thorough analysis. According to our proprietary Valuation Line, NEOGENOMICS’ fair value per share is around $27.2. This means that the current market price of $16.8 represents a 38.2% discount to the fair value, indicating that NEOGENOMICS is currently undervalued. Our users can take advantage of this discrepancy by purchasing its shares at their current price and reaping the benefits when it rises to its fair value. NeoGenomics_Ruling_on_Estimates”>More…
Peers
Its competitors include Dr Lalchandani Labs Ltd, Eurofins Scientific SE, and Quest Diagnostics Inc.
– Dr Lalchandani Labs Ltd ($BSE:541299)
Lalchandani Labs Ltd is a pharmaceutical company with a market cap of 134.33M as of 2022. The company has a Return on Equity of 10.86%. The company manufactures and markets generic drugs and pharmaceuticals.
– Eurofins Scientific SE ($LTS:0MV5)
Eurofins Scientific is a global leader in food, environmental, pharmaceutical and cosmetics products testing. With a network of over 800 laboratories in 47 countries, Eurofins offers a comprehensive range of services to clients globally. The company’s products and services are used by clients in the food, pharmaceutical, cosmetics, environmental, and consumer goods industries. Eurofins has a market cap of 12.5B as of 2022 and a ROE of 12.32%. The company’s products and services are used by clients in the food, pharmaceutical, cosmetics, environmental, and consumer goods industries.
– Quest Diagnostics Inc ($NYSE:DGX)
Quest Diagnostics is a medical testing company with a market cap of $16.36B as of 2022 and a ROE of 17.57%. The company provides diagnostic testing, information and services to patients, physicians and other healthcare providers. Quest Diagnostics is a leading provider of diagnostic testing, information and services. The company’s diagnostic testing helps to detect, diagnose and treat conditions and diseases. Quest Diagnostics also provides information and services to patients, physicians and other healthcare providers.
Summary
NeoGenomics is a specialized testing lab and cancer-focused genetic testing provider. Recently, a court ruling was made in favor of NeoGenomics that had limited impact on estimated growth and revenue, according to Needham & Company. Soon after, the stock price of NeoGenomics moved down. Despite this news, investors may be interested to note that there has been strong revenue and earnings growth in recent quarters, driven by an increase in demand for its services.
Additionally, the company has seen an increased interest in personalized medicine and clinical trials, which is likely to drive further growth in the future. As such, NeoGenomics remains a strong potential investment option for those looking to capitalize on the growing healthcare industry.
